Abstract

For adoptive cell transfer (ACT) immunotherapy of tumor-reactive T cells, an effective therapeutic outcome depends upon cell dose, cell expansion in vivo through a minimally differentiated phenotype, long term persistence, and strong cytolytic effector function. An incomplete understanding of the biological coupling between T cell expansion, differentiation, and response to stimulation hinders the co-optimization of these factors. We report on a biophysical investigation of how the short-term kinetics of T cell functional activation, through molecular stimulation and cell-cell interactions, competes with phenotype differentiation. T cells receive molecular stimulation for a few minutes to a few hours in bulk culture. Following this priming period, the cells are then analyzed at the transcriptional level, or isolated as single cells, with continuing molecular stimulation, within microchambers for analysis via 11-plex secreted protein assays. We resolve a rapid feedback mechanism, promoted by T cell—T cell contact interactions, which strongly amplifies T cell functional performance while yielding only minimal phenotype differentiation. When tested in mouse models of ACT, optimally primed T cells lead to complete tumor eradication. A similar kinetic process is identified in CD8+ and CD4+ T cells collected from a patient with metastatic melanoma.

Highlights

  • Adoptive cell therapy (ACT) of tumor-reactive T cells is being developed as a potentially curative treatment for patients with advanced cancer[1, 2]

  • Single cell proteomic and bulk transcriptomic kinetic studies were done on CD8+ tumor-antigen specific OT1 T cells isolated from the splenocytes of OT1 T cell receptor (TCR) transgenic mice

  • These cells were given a molecular stimulation of MHC class I tetramers loaded with the OVA peptide and the anti-CD28 antibody

Read more

Summary

Introduction

Adoptive cell therapy (ACT) of tumor-reactive T cells is being developed as a potentially curative treatment for patients with advanced cancer[1, 2]. For mouse models of ACT, a 7–10 day period of in vitro stimulation and incubation of tumor-antigen specific T cells can lead to the increased production of cytotoxic granules, but can yield terminally differentiated T cells[3, 4]. We carried out single cell biophysical kinetic experiments designed to separate the influence of these different interactions on T cell differentiation and gain of cytolytic effector function following in vitro stimulation. During T2, the effect of the T1 priming period is functionally evaluated We used this 24 hour kinetic study to identify an optimized set of T1 priming protocols for preparing a T cell ACT infusion product, which was tested in vivo using a mouse model of ACT. A model for describing the short-term kinetics of T cell activation is provided

Results
Discussion
Materials and methods
Methods and statistical analysis of immunohistochemistry

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.